On the public citation graph

Renal complications of Fabry disease in children

https://doi.org/10.1007/s00467-012-2222-9
0 signed · 105 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1007/bf00860748openalex-snapshot
Renal biopsy in children: indications, technique and efficacy in 119 consecutive cases
inferredcites →https://doi.org/10.1007/s00428-007-0468-6openalex-snapshot
Cellular and tissue localization of globotriaosylceramide in Fabry disease
inferredcites →https://doi.org/10.1007/s00467-006-0110-xopenalex-snapshot
Fabry disease and nephrogenic diabetes insipidus
inferredcites →https://doi.org/10.1007/s10545-006-0484-8openalex-snapshot
The Dutch Fabry cohort: Diversity of clinical manifestations and Gb3 levels
inferredcites →https://doi.org/10.1016/j.jpeds.2007.09.007openalex-snapshot
Safety and Efficacy of Enzyme Replacement Therapy with Agalsidase Beta: An International, Open-label Study in Pediatric Patients with Fabry Disease
inferredcites →https://doi.org/10.1016/j.ymgme.2007.09.013openalex-snapshot
Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry
inferredcites →https://doi.org/10.1016/s0140-6736(08)61589-5openalex-snapshot
Fabry's disease
inferredcites →https://doi.org/10.1016/s0140-6736(98)10363-xopenalex-snapshot
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria
inferredcites →https://doi.org/10.1016/s0272-6386(83)80047-xopenalex-snapshot
Early Renal Failure in Fabry's Disease
inferredcites →https://doi.org/10.1038/ki.1978.32openalex-snapshot
Early renal changes in hemizygous and heterozygous patients with Fabry's disease
inferredcites →https://doi.org/10.1038/ki.2009.398openalex-snapshot
Optimizing iohexol plasma disappearance curves to measure the glomerular filtration rate in children with chronic kidney disease
inferredcites →https://doi.org/10.1038/ki.2010.321openalex-snapshot
Cystatin C is not a better estimator of GFR than plasma creatinine in the general population
inferredcites →https://doi.org/10.1038/ki.2010.484openalex-snapshot
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease
inferredcites →https://doi.org/10.1038/sj.ki.5000208openalex-snapshot
Clinical benefit of enzyme replacement therapy in Fabry disease
inferredcites →https://doi.org/10.1053/j.ajkd.2005.01.036openalex-snapshot
Chronic Renal Failure and Proteinuria in Adulthood: Fabry Disease Predominantly Affecting the Kidneys
inferredcites →https://doi.org/10.1053/j.ajkd.2007.12.032openalex-snapshot
Renal Biopsy Findings in Children and Adolescents With Fabry Disease and Minimal Albuminuria
inferredcites →https://doi.org/10.1073/pnas.0712309105openalex-snapshot
Elevated globotriaosylsphingosine is a hallmark of Fabry disease
inferredcites →https://doi.org/10.1086/318809openalex-snapshot
A Phase 1/2 Clinical Trial of Enzyme Replacement in Fabry Disease: Pharmacokinetic, Substrate Clearance, and Safety Studies
inferredcites →https://doi.org/10.1086/504601openalex-snapshot
High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*
inferredcites →https://doi.org/10.1093/eurheartj/ehp387openalex-snapshot
Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease
inferredcites →https://doi.org/10.1093/ndt/12.1.221openalex-snapshot
Isolated glomerular proteinuria as the only clinical manifestation of Fabry's disease in an adult male
inferredcites →https://doi.org/10.1093/ndt/gfi152openalex-snapshot
Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting
inferredcites →https://doi.org/10.1093/ndt/gfp031openalex-snapshot
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy
inferredcites →https://doi.org/10.1093/ndt/gfp434openalex-snapshot
Renal biopsies in children: current practice and audit of outcomes
inferredcites →https://doi.org/10.1093/ndt/gfp528openalex-snapshot
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN)
inferredcites →https://doi.org/10.1093/ndt/gfp554openalex-snapshot
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry
inferredcites →https://doi.org/10.1093/ndt/gfp658openalex-snapshot
Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate
inferredcites →https://doi.org/10.1097/00005792-200203000-00003openalex-snapshot
Natural History of Fabry Renal Disease
inferredcites →https://doi.org/10.1097/01.asn.0000016684.07368.75openalex-snapshot
Renal Pathology in Fabry Disease
inferredcites →https://doi.org/10.1097/gim.0b013e3181bb05bbopenalex-snapshot
Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry Registry
inferredcites →https://doi.org/10.1097/gim.0b013e3181f13b75openalex-snapshot
Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature
inferredcites →https://doi.org/10.1111/j.1399-0004.2011.01671.xopenalex-snapshot
Fabry disease in children and response to enzyme replacement therapy: results from the Fabry Outcome Survey
inferredcites →https://doi.org/10.1111/j.1447-0756.1985.tb00045.xopenalex-snapshot
Early Prenatal Diagnosis of Inborn Error of Metabolism: A Case Report of a Fetus Affected with Fabry's Disease
inferredcites →https://doi.org/10.1111/j.1651-2227.2008.00700.xopenalex-snapshot
Cardiac manifestations of Anderson‐Fabry disease in children and adolescents
inferredcites →https://doi.org/10.1159/000168482openalex-snapshot
Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry Disease
inferredcites →https://doi.org/10.1159/000183006openalex-snapshot
Kidney Involvement in Systemic Lupus erythematosus and Fabry’s Disease
inferredcites →https://doi.org/10.1159/000320903openalex-snapshot
Blood Pressure, Proteinuria and Nephropathy in Fabry Disease
inferredcites →https://doi.org/10.1161/circulationaha.105.538132openalex-snapshot
Low-Grade Albuminuria and Incidence of Cardiovascular Disease Events in Nonhypertensive and Nondiabetic Individuals
inferredcites →https://doi.org/10.1186/1750-1172-6-69openalex-snapshot
Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients
inferredcites →https://doi.org/10.1203/pdr.0b013e318183f132openalex-snapshot
Characterization of Fabry Disease in 352 Pediatric Patients in the Fabry Registry
inferredcites →https://doi.org/10.1258/acb.2009.009007openalex-snapshot
How should proteinuria be detected and measured?
inferredcites →https://doi.org/10.1373/clinchem.2005.051557openalex-snapshot
Simple Cystatin C–Based Prediction Equations for Glomerular Filtration Rate Compared with the Modification of Diet in Renal Disease Prediction Equation for Adults and the Schwartz and the Counahan–Barratt Prediction Equations for Children
inferredcites →https://doi.org/10.1542/peds.2005-2895openalex-snapshot
Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease
inferredcites →https://doi.org/10.1681/asn.2006080816openalex-snapshot
Sustained, Long-Term Renal Stabilization After 54 Months of Agalsidase β Therapy in Patients with Fabry Disease
inferredcites →https://doi.org/10.1681/asn.2006121400openalex-snapshot
Antiproteinuric Therapy and Fabry Nephropathy
inferredcites →https://doi.org/10.1681/asn.2008080870openalex-snapshot
Agalsidase Alfa and Kidney Dysfunction in Fabry Disease
inferredcites →https://doi.org/10.2165/11318300-000000000-00000openalex-snapshot
Enzyme Replacement Therapy for Fabry Disease
inferredcites →https://doi.org/10.2215/cjn.01640309openalex-snapshot
Measurement and Estimation of GFR in Children and Adolescents
inferredcites →https://doi.org/10.2215/cjn.04340510openalex-snapshot
Prognostic Indicators of Renal Disease Progression in Adults with Fabry Disease
inferredcites →https://doi.org/10.2215/cjn.06090809openalex-snapshot
Biomarkers of Fabry Disease Nephropathy
inferredcites →https://doi.org/10.5414/cnp71118openalex-snapshot
The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function
inferredcites →https://doi.org/10.7326/0003-4819-139-4-200308190-00006openalex-snapshot
Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis
inferredcites →https://doi.org/10.7326/0003-4819-146-2-200701160-00148openalex-snapshot
Agalsidase-Beta Therapy for Advanced Fabry Disease

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4631081openalex-extracted
inferred← citeshttps://doi.org/10.1002/9781118441213.rtd0154openalex-snapshot
The Skin and Disorders of the Kidney and Urinary Tract
inferred← citeshttps://doi.org/10.1002/9781119709268.rook154openalex-snapshot
The Skin and Disorders of the Kidney and Urinary Tract
inferred← citeshttps://doi.org/10.1002/jmd2.12201openalex-snapshot
Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants
inferred← citeshttps://doi.org/10.1007/978-3-031-17759-0_27openalex-snapshot
Fabry Nephropathy
inferred← citeshttps://doi.org/10.1007/978-3-319-76148-0_4openalex-snapshot
Fabry Disease
inferred← citeshttps://doi.org/10.1007/978-3-642-27843-3_79-1openalex-snapshot
Inherited Glomerular Diseases
inferred← citeshttps://doi.org/10.1007/978-3-642-54671-6_357-1openalex-snapshot
Sphingolipidosen
inferred← citeshttps://doi.org/10.1007/978-3-662-43596-0_79openalex-snapshot
Inherited Glomerular Diseases
inferred← citeshttps://doi.org/10.1007/978-3-662-60300-0_357openalex-snapshot
Sphingolipidosen
inferred← citeshttps://doi.org/10.1007/s00216-014-8402-7openalex-snapshot
Fabry disease: renal sphingolipid distribution in the α-Gal A knockout mouse model by mass spectrometric and immunohistochemical imaging
inferred← citeshttps://doi.org/10.1007/s00431-013-2118-0openalex-snapshot
A case of Fabry nephropathy with histological features of oligonephropathy
inferred← citeshttps://doi.org/10.1007/s00467-013-2652-zopenalex-snapshot
Lysosome dysfunction in the pathogenesis of kidney diseases
inferred← citeshttps://doi.org/10.1007/s00467-018-4006-3openalex-snapshot
Clinical parameters, LysoGb3, podocyturia, and kidney biopsy in children with Fabry disease: is a correlation possible?
inferred← citeshttps://doi.org/10.1007/s00467-023-06050-5openalex-snapshot
Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease
inferred← citeshttps://doi.org/10.1007/s10157-020-01986-6openalex-snapshot
Kidney biopsy guidebook 2020 in Japan
inferred← citeshttps://doi.org/10.1007/s11845-017-1625-9openalex-snapshot
Auditing the frequency and the clinical and economic impact of testing for Fabry disease in patients under the age of 70 with a stroke admitted to Saint Vincent’s University Hospital over a 6-month period
inferred← citeshttps://doi.org/10.1016/b978-0-12-407710-2.00016-3openalex-snapshot
Neurologic Dysfunction and Kidney Disease
inferred← citeshttps://doi.org/10.1016/j.jflm.2016.05.008openalex-snapshot
Sudden death following AV node ablation in a man with Fabry disease mimicking hypertrophic cardiomyopathy
inferred← citeshttps://doi.org/10.1016/j.kint.2023.09.011openalex-snapshot
Development of an automated estimation of foot process width using deep learning in kidney biopsies from patients with Fabry, minimal change, and diabetic kidney diseases
inferred← citeshttps://doi.org/10.1016/j.ymgme.2017.05.007openalex-snapshot
New biomarkers defining a novel early stage of Fabry nephropathy: A diagnostic test study
inferred← citeshttps://doi.org/10.1016/j.ymgme.2019.10.010openalex-snapshot
Pathogenesis of Fabry nephropathy: The pathways leading to fibrosis
inferred← citeshttps://doi.org/10.1016/j.ymgme.2022.07.010openalex-snapshot
An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease
inferred← citeshttps://doi.org/10.1016/j.ymgme.2023.107585openalex-snapshot
An expert consensus on the recommendations for the use of biomarkers in Fabry disease
inferred← citeshttps://doi.org/10.1016/j.ymgmr.2022.100851openalex-snapshot
Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype
inferred← citeshttps://doi.org/10.1016/j.ymthe.2024.11.021openalex-snapshot
Longitudinal imaging of therapeutic enzyme expression after gene therapy for Fabry disease using positron emission tomography and the radiotracer [18F]AGAL
inferred← citeshttps://doi.org/10.1038/gim.2014.120openalex-snapshot
Fabry disease in infancy and early childhood: a systematic literature review
inferred← citeshttps://doi.org/10.1080/0886022x.2026.2702129openalex-snapshot
Clinical manifestations, diagnosis, and management of renal involvement in Fabry disease
inferred← citeshttps://doi.org/10.1093/ckj/sfae194openalex-snapshot
Reduction in kidney function decline and risk of severe clinical events in agalsidase beta–treated Fabry disease patients: a matched analysis from the Fabry Registry
inferred← citeshttps://doi.org/10.1111/cge.13546openalex-snapshot
Consensus recommendations for diagnosis, management and treatment of Fabry disease in paediatric patients
inferred← citeshttps://doi.org/10.1111/jpc.12732openalex-snapshot
Diagnostic dilemma and delay in F abry disease: Insights from a case series of young female patients
inferred← citeshttps://doi.org/10.1136/jmedgenet-2019-106030openalex-snapshot
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease
inferred← citeshttps://doi.org/10.1159/000488121openalex-snapshot
Fabry Nephropathy: An Evidence-Based Narrative Review
inferred← citeshttps://doi.org/10.1177/0300060519891290openalex-snapshot
IgA nephropathy suspected to be combined with Fabry disease or Alport syndrome: a case report
inferred← citeshttps://doi.org/10.1371/journal.pone.0112188openalex-snapshot
Mosaicism of Podocyte Involvement Is Related to Podocyte Injury in Females with Fabry Disease
inferred← citeshttps://doi.org/10.1371/journal.pone.0136442openalex-snapshot
Epithelial–Mesenchymal Transition in Kidney Tubular Epithelial Cells Induced by Globotriaosylsphingosine and Globotriaosylceramide
inferred← citeshttps://doi.org/10.1371/journal.pone.0152812openalex-snapshot
One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease
inferred← citeshttps://doi.org/10.1590/2175-8239-jbn-2021-0216openalex-snapshot
Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN)
inferred← citeshttps://doi.org/10.1590/2326-4594-jiems-2021-0028openalex-snapshot
Clinical and diagnostic aspects of Fabry disease management: a narrative review with a particular focus on Brazilian experts’ perspectives
inferred← citeshttps://doi.org/10.17116/jnevro20161169198-105openalex-snapshot
The neurological manifestations of Fabry disease. A review
inferred← citeshttps://doi.org/10.18359/rlbi.4642openalex-snapshot
Enfermedad de Fabry clásica en pacientes pediátricos asintomáticos
inferred← citeshttps://doi.org/10.21037/tau-20-1260openalex-snapshot
Diagnostic value of urinary exosomal miR-23b-3p, miR-30a-5p, and miR-151-3p in children with primary nephrotic syndrome
inferred← citeshttps://doi.org/10.29039/2224-6444-2025-15-1-64-70openalex-snapshot
MORPHOLOGICAL CHANGES IN THE KIDNEYS IN FABRY DISEASE
inferred← citeshttps://doi.org/10.3390/cells10020245openalex-snapshot
RIPK3 Contributes to Lyso-Gb3-Induced Podocyte Death
inferred← citeshttps://doi.org/10.3390/nu16071061openalex-snapshot
Diet and Physical Activity in Fabry Disease: A Narrative Review
inferred← citeshttps://doi.org/10.3978/j.issn.2224-4336.2015.12.02openalex-snapshot
Paediatric Fabry disease.
inferred← citeshttps://doi.org/10.4132/jptm.2025.12.10openalex-snapshot
Drug-induced phospholipidosis of the kidney suspected to be caused by atomoxetine
inferred← citeshttps://doi.org/10.4236/ojneph.2018.83009openalex-snapshot
Urinary Excretion of microRNAs in Young Fabry Disease Patients with Mild or Absent Nephropathy
inferred← citeshttps://doi.org/10.4274/balkanmedj.galenos.2024.2023-10-98openalex-snapshot
Serum Neopterin, Biopterin, Tryptophan, and Kynurenine Levels in Patients with Fabry Disease
inferred← citeshttps://doi.org/10.5200/sm-hs.2013.137openalex-snapshot
FABRY NEFROPATIJA
inferred← citeshttps://doi.org/10.5301/pocj.5000203openalex-snapshot
The Management of Fabry Nephropathy
inferred← citeshttps://doi.org/10.5414/cncs107994openalex-snapshot
Is there a pathogenic association between Fabry’s disease and IgA nephropathy?
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.